^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    SMARCA4 deletion + dMMR/MSI-H + PD-L1 underexpression

    i
    Other names: SMARCA4, SWI/SNF Related, Matrix Associated, Actin Dependent Regulator Of Chromatin, Subfamily A, Member 4, Mitotic Growth And Transcription Activator, ATP-Dependent Helicase SMARCA4, Global Transcription Activator Homologous Sequence, Transcription Activator BRG1, Sucrose Nonfermenting-Like 4, BRG1-Associated Factor 190A, Protein Brahma Homolog 1, BRM/SWI2-Related Gene 1, Homeotic Gene Regulator, Brahma Protein-Like 1, Nuclear Protein GRB1, Protein BRG-1, SNF2-Like 4, SNF2-Beta, BAF190A, SNF2L4, BRG1,BAF190, SNF2LB, HSNF2b, MRD16, RTPS2, SNF2B, CSS4, SNF2, SWI2, MSI-H, Microsatellite instability - high, dMMR, PD-L1, CD274, HPD-L1, PD-L1, B7H1, PDL1, Programmed death ligand 1, B7-H1, B7-H, PDCD1L1, PDCD1LG1, PDCD1 Ligand 1, B7 homolog 1, CD274 Antigen, Programmed cell death 1 ligand 1, CD274 molecule
    Entrez ID:
    29126; 6597
    Related biomarkers:
    Expression
    Mutation
    CNA
    Others
    almost2years
    SMARCA4-deficient Undifferentiated Lung Carcinoma with Additional Microsatellite Instability Mixed Response to Pembrolizumab Followed by Hyperprogression – A Cautionary Tale Highlighting the Pitfalls to Tumor Agnostic Drug Approvals (IASLC-TTLC 2023)
    Initial MDTB recommendations including definitive chemo-RT with subsequent consolidation durvalumab were not ideal due large primary tumor and low performance status. Extrapolating from other tumor types’ outcome data may not translate as optimistically to NSCLC. Further review of population-based data on dMMR/MSI-H NSCLC and SMARCA-4UT is warranted to elucidate outcomes of PD-1 inhibitor treatment on these tumor types
    Microsatellite instability • MSi-H Biomarker • PD(L)-1 Biomarker • IO biomarker • Pan tumor
    |
    PD-L1 (Programmed death ligand 1) • MSI (Microsatellite instability) • SMARCA4 (SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily A, member 4)
    |
    MSI-H/dMMR • PD-L1 underexpression • PD-1-L • PD-L1-L • SMARCA4 deletion + dMMR/MSI-H + PD-L1 underexpression
    |
    Keytruda (pembrolizumab) • Imfinzi (durvalumab)